AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MMS
  4. [Form 4] MAXIMUS, Inc. Insider Trading Activity

[Form 4] MAXIMUS, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ilene Baylinson, General Manager - Health & Human at MAXIMUS, Inc. (MMS), received dividend equivalent rights on 08/31/2025 that converted to the economic equivalent of 129.906 shares of MAXIMUS common stock. These rights accrue alongside previously awarded restricted stock units and certain performance share units where performance criteria were met. Following the reported accrual, Ms. Baylinson beneficially owns 38,201.195 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing discloses a routine equity accrual tied to awards rather than an open-market trade or option exercise.

Ilene Baylinson, General Manager - Health & Human presso MAXIMUS, Inc. (MMS), ha ricevuto il 31/08/2025 diritti equivalenti a dividendi che si sono convertiti nell'equivalente economico di 129.906 azioni ordinarie di MAXIMUS. Questi diritti si cumulano con unit脿 azionarie vincolate gi脿 assegnate e con alcune unit脿 azionarie legate alla performance per le quali sono stati soddisfatti i criteri. Dopo l'accrual segnalato, la Sig.ra Baylinson detiene beneficiariamente 38,201.195 azioni in propriet脿 diretta. Il Modulo 4 猫 stato firmato per procura il 03/09/2025. La comunicazione indica un semplice accredito di azioni legato a premi, non una transazione sul mercato aperto n茅 l'esercizio di opzioni.

Ilene Baylinson, Directora General - Health & Human en MAXIMUS, Inc. (MMS), recibi贸 el 31/08/2025 derechos equivalentes a dividendos que se convirtieron en el equivalente econ贸mico de 129.906 acciones ordinarias de MAXIMUS. Estos derechos se acumulan junto con unidades restringidas de acciones previamente otorgadas y con ciertas unidades por desempe帽o cuyos criterios se cumplieron. Tras el devengo informado, la Sra. Baylinson posee beneficiariamente 38,201.195 acciones en propiedad directa. El Formulario 4 fue firmado por un apoderado el 03/09/2025. La presentaci贸n revela un devengo de capital rutinario vinculado a concesiones, no una operaci贸n en mercado abierto ni el ejercicio de opciones.

Ilene Baylinson鞚� MAXIMUS, Inc.(MMS)鞚� General Manager - Health & Human鞙茧靹� 2025-08-31鞐� 氚半嫻 霃欖澕 甓岆Μ毳� 攵�鞐皼鞎橁碃, 鞚措姅 MAXIMUS 氤错喌欤� 129.906欤检棎 頃措嫻頃橂姅 瓴届牅鞝� 臧�旃橂 鞝勴櫂霅橃棃鞀惦媹雼�. 鞚� 甓岆Μ電� 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤� 雼渼 氚� 靹标臣 旮办鞚� 於╈”霅� 鞚茧秬 靹标臣 欤检嫕 雼渼鞕� 頃粯 鞝侂霅╇媹雼�. 氤搓碃霅� 鞝侂 鞚错泟 Baylinson 鞌姅 歆侅爲 氤挫湢 順曧儨搿� 齑� 38,201.195欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Form 4電� 2025-09-03鞐� 鞙勳瀯 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟. 鞝滌稖 靹滊電� 瓿店皽 鞁滌灔 瓯半灅雮� 鞓奠厴 頄夓偓氤措嫟電� 靸侅棳鞐� 霐半ジ 鞝曣赴鞝侅澑 欤检嫕 鞝侂鞚� 氚濏瀳瓿� 鞛堨姷雼堧嫟.

Ilene Baylinson, Directrice g茅n茅rale 鈥� Health & Human chez MAXIMUS, Inc. (MMS), a re莽u le 31/08/2025 des droits 茅quivalents aux dividendes qui se sont convertis en l'茅quivalent 茅conomique de 129.906 actions ordinaires MAXIMUS. Ces droits s'accumulent avec des unit茅s d'actions restreintes pr茅c茅demment attribu茅es et certaines unit茅s li茅es 脿 la performance dont les crit猫res ont 茅t茅 remplis. Apr猫s l'enregistrement de cet accrual, Mme Baylinson d茅tient b茅n茅ficiairement 38,201.195 actions en propri茅t茅 directe. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire le 03/09/2025. Le d茅p么t r茅v猫le un simple accrual d'actions li茅 脿 des attributions, et non une transaction sur le march茅 ou l'exercice d'options.

Ilene Baylinson, General Manager 鈥� Health & Human bei MAXIMUS, Inc. (MMS), erhielt am 31.08.2025 Dividenden-脛quivalenzrechte, die in den wirtschaftlichen Gegenwert von 129.906 Stammaktien von MAXIMUS umgewandelt wurden. Diese Rechte werden zusammen mit zuvor gew盲hrten Restricted Stock Units und bestimmten Performance Share Units, deren Leistungsziele erreicht wurden, angesammelt. Nach dem gemeldeten Ansammeln besitzt Frau Baylinson wirtschaftlich direkt 38,201.195 Aktien. Das Formblatt 4 wurde am 03.09.2025 von einem Bevollm盲chtigten unterschrieben. Die Meldung weist auf eine routinem盲脽ige Aktiengutschrift im Zusammenhang mit Zuwendungen hin, nicht auf einen Handel am offenen Markt oder die Aus眉bung von Optionen.

Positive
  • Transparent disclosure of dividend-equivalent rights accrual and resulting direct beneficial ownership
  • Alignment with compensation structure through dividend equivalents tied to RSUs and vested PSUs
Negative
  • None.

Insights

TL;DR: Routine accrual of dividend-equivalent rights increased direct holdings by 129.906 shares; immaterial market impact.

The filing documents a common, non-market transaction where dividend equivalent rights tied to RSUs and vested PSUs were credited to the reporting person. The incremental 129.906 shares raise direct beneficial ownership to 38,201.195 shares. This is an administrative equity accrual reflecting compensation mechanics, not an active purchase or sale. For investors, the transaction signals ongoing equity-based compensation alignment with management but provides no new information on operating performance or capital allocation.

TL;DR: Disclosure is standard and consistent with executive compensation practices; no governance red flags.

The Form 4 properly discloses the nature and amount of dividend equivalent rights and ties them to existing RSUs/PSUs, indicating compliance with Section 16 reporting. The use of an attorney-in-fact to file is acceptable and dated 09/03/2025. There is no indication of unusual timing or related-party transactions in the filing text provided.

Ilene Baylinson, General Manager - Health & Human presso MAXIMUS, Inc. (MMS), ha ricevuto il 31/08/2025 diritti equivalenti a dividendi che si sono convertiti nell'equivalente economico di 129.906 azioni ordinarie di MAXIMUS. Questi diritti si cumulano con unit脿 azionarie vincolate gi脿 assegnate e con alcune unit脿 azionarie legate alla performance per le quali sono stati soddisfatti i criteri. Dopo l'accrual segnalato, la Sig.ra Baylinson detiene beneficiariamente 38,201.195 azioni in propriet脿 diretta. Il Modulo 4 猫 stato firmato per procura il 03/09/2025. La comunicazione indica un semplice accredito di azioni legato a premi, non una transazione sul mercato aperto n茅 l'esercizio di opzioni.

Ilene Baylinson, Directora General - Health & Human en MAXIMUS, Inc. (MMS), recibi贸 el 31/08/2025 derechos equivalentes a dividendos que se convirtieron en el equivalente econ贸mico de 129.906 acciones ordinarias de MAXIMUS. Estos derechos se acumulan junto con unidades restringidas de acciones previamente otorgadas y con ciertas unidades por desempe帽o cuyos criterios se cumplieron. Tras el devengo informado, la Sra. Baylinson posee beneficiariamente 38,201.195 acciones en propiedad directa. El Formulario 4 fue firmado por un apoderado el 03/09/2025. La presentaci贸n revela un devengo de capital rutinario vinculado a concesiones, no una operaci贸n en mercado abierto ni el ejercicio de opciones.

Ilene Baylinson鞚� MAXIMUS, Inc.(MMS)鞚� General Manager - Health & Human鞙茧靹� 2025-08-31鞐� 氚半嫻 霃欖澕 甓岆Μ毳� 攵�鞐皼鞎橁碃, 鞚措姅 MAXIMUS 氤错喌欤� 129.906欤检棎 頃措嫻頃橂姅 瓴届牅鞝� 臧�旃橂 鞝勴櫂霅橃棃鞀惦媹雼�. 鞚� 甓岆Μ電� 鞚挫爠鞐� 攵�鞐悳 鞝滍暅欤� 雼渼 氚� 靹标臣 旮办鞚� 於╈”霅� 鞚茧秬 靹标臣 欤检嫕 雼渼鞕� 頃粯 鞝侂霅╇媹雼�. 氤搓碃霅� 鞝侂 鞚错泟 Baylinson 鞌姅 歆侅爲 氤挫湢 順曧儨搿� 齑� 38,201.195欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Form 4電� 2025-09-03鞐� 鞙勳瀯 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟. 鞝滌稖 靹滊電� 瓿店皽 鞁滌灔 瓯半灅雮� 鞓奠厴 頄夓偓氤措嫟電� 靸侅棳鞐� 霐半ジ 鞝曣赴鞝侅澑 欤检嫕 鞝侂鞚� 氚濏瀳瓿� 鞛堨姷雼堧嫟.

Ilene Baylinson, Directrice g茅n茅rale 鈥� Health & Human chez MAXIMUS, Inc. (MMS), a re莽u le 31/08/2025 des droits 茅quivalents aux dividendes qui se sont convertis en l'茅quivalent 茅conomique de 129.906 actions ordinaires MAXIMUS. Ces droits s'accumulent avec des unit茅s d'actions restreintes pr茅c茅demment attribu茅es et certaines unit茅s li茅es 脿 la performance dont les crit猫res ont 茅t茅 remplis. Apr猫s l'enregistrement de cet accrual, Mme Baylinson d茅tient b茅n茅ficiairement 38,201.195 actions en propri茅t茅 directe. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire le 03/09/2025. Le d茅p么t r茅v猫le un simple accrual d'actions li茅 脿 des attributions, et non une transaction sur le march茅 ou l'exercice d'options.

Ilene Baylinson, General Manager 鈥� Health & Human bei MAXIMUS, Inc. (MMS), erhielt am 31.08.2025 Dividenden-脛quivalenzrechte, die in den wirtschaftlichen Gegenwert von 129.906 Stammaktien von MAXIMUS umgewandelt wurden. Diese Rechte werden zusammen mit zuvor gew盲hrten Restricted Stock Units und bestimmten Performance Share Units, deren Leistungsziele erreicht wurden, angesammelt. Nach dem gemeldeten Ansammeln besitzt Frau Baylinson wirtschaftlich direkt 38,201.195 Aktien. Das Formblatt 4 wurde am 03.09.2025 von einem Bevollm盲chtigten unterschrieben. Die Meldung weist auf eine routinem盲脽ige Aktiengutschrift im Zusammenhang mit Zuwendungen hin, nicht auf einen Handel am offenen Markt oder die Aus眉bung von Optionen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Baylinson Ilene R.
(Last) (First) (Middle)
C/O MAXIMUS INC.
1600 TYSONS BLVD, STE 1400
(Street)
MCLEAN VA 22102
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MAXIMUS, INC. [ MMS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Mgr - Health & Human
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Dividend Equivalent Rights (1) 08/31/2025 A 129.906 (1) (1) Common Stock 129.906 $0 38,201.195 D
Explanation of Responses:
1. Dividend equivalent rights accrued on previously-awarded restricted stock units ("RSU") which vest proportionately with RSUs to which they relate and on certain performance share units ("PSUs") where the performance criteria of such PSUs have been met. Each dividend equivalent right is the economic equivalent of one share of Maximus Common stock.
/s/ John T Martinez: As Attorney-In-Fact for: Ilene Baylinson 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Ilene Baylinson report on the MAXIMUS (MMS) Form 4?

The Form 4 reports that Ms. Baylinson received 129.906 dividend-equivalent rights on 08/31/2025, increasing her direct beneficial ownership to 38,201.195 shares.

Were the reported shares from a market trade or compensation?

The shares are the economic equivalent of dividend equivalent rights tied to previously awarded RSUs and certain PSUs, indicating compensation-related accrual, not an open-market trade.

What is the reporting person's role at MAXIMUS?

The reporting person is listed as General Manager - Health & Human, and the Form 4 indicates she is an officer and director-level reporting person.

When was the Form 4 filed and who signed it?

The underlying transaction date is 08/31/2025 and the Form 4 was signed by an attorney-in-fact on 09/03/2025.
Stock MMS logo
Maximus

NYSE:MMS

MMS Rankings

#1361 Ranked by Market Cap
#1836 Ranked by Dividends

MMS Latest News

Sep 10, 2025
Maximus Board Authorizes Expansion to Purchase Program of Maximus Common Stock
Aug 19, 2025
Maximus Achieves Cybersecurity Maturity Model Certification (CMMC) Level 2
Aug 7, 2025
Maximus Reports Fiscal Year 2025 Third Quarter Results
Jul 28, 2025
Maximus Awarded $77 Million Advanced Cybersecurity Services Contract to Support Critical Air Force Cyber Command and Control Systems
Jul 10, 2025
Maximus Schedules Fiscal 2025 Third Quarter Conference Call

MMS Latest SEC Filings

Sep 10, 2025
[8-K] MAXIMUS, Inc. Reports Material Event
Sep 3, 2025
[Form 4] MAXIMUS, Inc. Insider Trading Activity
Sep 3, 2025
[Form 4] MAXIMUS, Inc. Insider Trading Activity
Sep 3, 2025
[Form 4] MAXIMUS, Inc. Insider Trading Activity
Sep 3, 2025
[Form 4] MAXIMUS, Inc. Insider Trading Activity

MMS Stock Data

4.98B
55.65M
1.08%
104.07%
4.49%
Specialty Business Services
Services-business Services, Nec
United States
MCLEAN